| Drug Name: | Tobramycin (32986-56-4) |
|---|---|
| PubChem ID: | 36294 |
| SMILES: | C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N |
| InchiKey: | NLVFBUXFDBBNBW-PBSUHMDJSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents |
| Molecular Weight (dalton) | : | 467.52 |
| LogP | : | -6.2958 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 14 |
| Hydrogen Bond Donor Count | : | 10 |
| Total Polar Surface Area | : | 268.17 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Cephalothin (153-61-7) | Nephrotoxicity | Additive | Uncertain. The nephrotoxic effects of tobramycin is well documented, and some (mostly older) cephalosporins are known to be nephrotoxic, especially in high dose. However, it appears that doses that are well tolerated separately can be nephrotoxic when given together | Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients |
| Piperacillin (66258-76-2) | Nephrotoxicity | Antagonistic | The nephrotoxic effects of tobramicin is well documented. The reason why piperacillin increase the risk of nephrotoxicity is not clear. One suggestion is that sodium loading may protect the kidney from tobramycin toxicity and piperacillin has only 40% as much sodium | In vivo inactivation of tobramycin by piperacillin |
| Vancomycin (1404-90-6) | Nephrotoxicity | Additive | Not clear | Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy |
This panel provides drug-protein interaction and their ADRs along with references
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category